<DOC>
	<DOC>NCT00284934</DOC>
	<brief_summary>This study introduces a new optimization immunosuppressive regimen associating tacrolimus at a reduced dose and enteric-coated mycophenolate sodium at an increased dose in order to slow down renal function worsening and to prevent the progression of chronic allograft nephropathy, while maintaining the same efficacy, in maintenance renal transplant recipients.</brief_summary>
	<brief_title>Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Primary or secondary kidney transplant Treatment with mycophenolic acid (MMF 1 g/d or ECMPS 720 mg/d) and tacrolimus (trough concentration [C0] ≥ 5.5 ng/mL) Creatinine clearance ≥ 30 mL/min and &lt; 60 mL/min and stable renal function Multiorgan recipients or previous transplant with any other organ different from kidney Biopsy proven acute rejection or treated acute rejection within the last 3 months. Prescription of mycophenolate mofetil 1 g/d or mycophenolate sodium 720 mg/d due to adverse event occurrence when higher doses were administered Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Dose optimization</keyword>
	<keyword>immune suppressive regimen</keyword>
	<keyword>enteric-coated mycophenolate sodium</keyword>
	<keyword>EC-MPS</keyword>
	<keyword>renal transplantation</keyword>
	<keyword>kidney</keyword>
	<keyword>transplant</keyword>
	<keyword>maintenance patients</keyword>
	<keyword>Renal transplantation in maintenance</keyword>
</DOC>